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EDITORIAL
Talking at cross purposes: Molecular interactions
downstream from TGF-
In the mists of signal transduction antiquity (10 to 15 of the target gene. Modulating interactions among path-
years ago), the path from the cell membrane to the nu- ways can occur at or between any of these levels.
cleus was a simple one. Ligand binding had been found In this issue of Kidney International, Zdunek and col-
to stimulate activation of a second messenger that con- leagues describe one example of cross-talk between two
veyed a biochemical signal into the cell. This observation signaling systems, those induced by transforming growth
was augmented by a profusion of molecular applications factor (TGF)- and by estrogen [1]. Ostensibly, these
that were used to define mechanisms regulating gene ex- pathways are quite different. TGF- signals through a
pression. In particular, the identification and study of serine/threonine kinase receptor that activates a group
trans-acting molecules (transcription factors) permitted of signaling molecules called Smads. These in turn partic-
the delineation of several direct pathways between li- ipate in the formation of a transcription regulatory com-
gand-stimulated signals and the nucleus. The tremen- plex in the nucleus [2]; this pathway mediates TGF-–
dous growth of knowledge in this area was stimulated by stimulated mesangial cell collagen expression [3]. In con-
the characterization of relatively undifferentiated, trans- trast, estrogen binds to a cytoplasmic receptor that, after
formed cell lines that lacked many elements of the signal- ligand binding, classically is targeted directly to the nu-
ing machinery. In these cells, individual components of cleus as a transcriptional regulator [4]. Mesangial cells ex-
signaling pathways could be ectopically expressed and press a responsive estrogen receptor [5]. Previous work
their actions analyzed. by Zdunek’s colleagues has indicated that estradiol de-
One drawback of this approach, however, is its relative creases mesangial cell collagen expression. However, the
artificiality. As investigators sought to study these newly molecular mechanisms of this effect have not been fully
identified pathways in more differentiated cells, their defined. Now, the authors describe a system in cultured
results were inconsistent and sometimes contradictory. murine mesangial cells in which TGF- stimulates the
Differences from the initial studies could reflect the fact activity of casein kinase II (CK2), an action known to
that primary cell cultures are not transformed (transfor- increase the phosphorylation of the signaling molecule,
mation is essentially a process that bypasses usual signal Egr-1. This, in turn, decreases Egr-1 binding to the Sp1
transduction check-points); that the signals being studied transcription factor. In the mesangial cells, a result is that
reflect endogenous molecules rather than artificially ex- more Sp1 is available to bind to the 1/2(IV) collagen
pressed ones; or that the cells being studied were now promoter, increasing gene activation and protein synthe-
more differentiated. This last point should be obvious, sis. Estradiol decreases these effects by inhibiting CK2
in that it is the very differences in how cells respond activity, leading the authors to propose that this model
to signal activation that define their tissue specificity. provides a mechanism by which estrogen could decrease
Differences in responses may be subtle, and they reflect mesangial cell fibrogenesis, perhaps accounting for ob-
the complex milieu within the cells. A new paradigm served gender differences in the outcome of certain ex-
was developed, in which there is cross-talk among the perimental and clinical renal lesions.
different pathways that are present in a given cell. In addition to providing us with an explanation for
The issue of cross-talk has been the subject of consider- clinically observable examples of sexual dimorphism in
able investigation. Interaction among putatively distinct the renal fibrogenic response (references cited in the
signal transduction pathways could occur at multiple points. Zdunek paper), the results open a virtual Pandora’s box
Signaling can be regulated at the levels of receptor ex- of various levels of cross-talk. The potential role of se-
pression and activation, expression of intermediate sig- rum, in providing both TGF-–like CK2-activating activ-
naling molecules, the degree of activation of these mole- ity [1] and growth factor stimulation of additional signal-
cules, their movement within the cell, their interaction ing pathways such as mitogen-activated protein (MAP)
with transcription factors, or transcriptional regulation kinases that could interact with Smads [6], is an impor-
tant caveat for studies in the field. Estrogen itself may
stimulate growth factor-like signaling [7]. Moreover, nu-
merous additional pathways have been shown to interact 2001 by the International Society of Nephrology
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